Nicarbazin (nicarbazine) is incorporated almost exclusively through the feed route in commercial broiler production because its aqueous solubility places true drinking-water medication outside the usual formulation window; dry premix design therefore centers on particle-size matching between API and carrier, controlled dilution, and mixer discharge CV. In a 25% w/w nicarbazin premix, a complete-feed target of 100–125 mg/kg active requires 400–500 g of premix per 1000 kg finished feed; where a destination market enforces a lower authorised maximum, the same premix must be reduced proportionally, for example to 160 g/ton at a 40 mg/kg active target. Regulatory controls for this segment include European Union feed-additive authorisation under Regulation (EC) No 1831/2003 and the Union Register of Feed Additives entry for the coccidiostat category, while US-compliant shipments fall within 21 CFR Part 558 medicated feed provisions and the corresponding label withdrawal period. Modern feed-mill practice pre-blends the neat API into a 25% w/w premix using a horizontal paddle mixer or double-ribbon mixer with coefficient of variation ≤5%; the premix is then metered into a 1000 kg main mixer before pellets or mash are discharged. Pneumatic conveying after the first pre-blend can stratify fines if the API and carrier differ strongly in tapped bulk density; vacuum receivers should therefore be positioned directly above the mixer inlet, and dense-phase transfer is preferred over dilute-phase conveying. Thermal processing introduces a second control point because the premix is frequently added after pelleting or through a conditioner bypass when stability data do not support a specific residence time at 85–90°C. Terminal products are pelleted broiler rations, crumbled starter feeds, and post-pelleting meal finishes; for food-producing species, residue status and withdrawal periods must be checked against the Union Register entry and Table 1 of the Annex to Commission Regulation (EU) No 37/2010 before the finished feed is dispatched.

What process controls prevent segregation in low-dust nicarbazin granule batches?

Wet granulation of nicarbazin premixes reduces airborne carryover and dust losses but introduces a second regulatory boundary: residual moisture and drying temperature must not compromise the equimolar complex of 4,4'-dinitrocarbanilide and 2-hydroxy-4,6-dimethylpyrimidine. A low-dust granulated premix at 5% w/w nicarbazin is metered at 2–2.5 kg per 1000 kg complete feed to deliver 100–125 mg/kg active; the granule carrier is typically a lactose–starch or corncob granular base with 2–4% w/w povidone K30 as binder and 0.5–1.5% w/w of a hydrophilic fumed silica flow aid. Process reliability is measured by sieve retention and tap density rather than absolute granule hardness, because the target is low segregation in silo discharge and auger transfer. Fluid-bed top-spray granulation with inlet air 60–70°C, product temperature 35–45°C, and final loss on drying <2% w/w is used when the API must remain close to its original polymorphic state; high-shear granulation with impeller speed 250–400 rpm and chopper speed 1500–3000 rpm is faster but requires post-milling sieving through 150–400 µm screens to remove oversized agglomerates. Compliance for the granulation step falls under Regulation (EC) No 1831/2003 for feed-additive function and under current Good Manufacturing Practice for veterinary feed additives, with FAMI-QS certification used for cross-border EU deliveries; particle-size verification is performed by laboratory sieve analysis according to ASTM E11 or laser diffraction according to ISO 13320. Terminal products are low-dust granular premixes, microgranulated feed additives, and foil-sealed sachets for direct addition to farm-scale mixers; granulated material packed in low-moisture vapour-barrier liners should be tested for loss on drying after 48 h at 40°C and 75% RH if export containers are expected to cross high-humidity zones.

Compressed oral tablets and capsules for coccidiosis management in non-food avian species

Direct compression of nicarbazin into oral tablets for pigeons, zoo birds, and other non-food avian species is constrained more by API cohesion and electrostatic charging than by chemical instability. A 25 mg unit dose prepared with 20% w/w drug load yields a 125 mg total tablet mass; compressed tablets at 5–10% w/w nicarbazin improve content uniformity on non-specialized tablet presses but demand a higher excipient mass and may increase segregation risk in the hopper. Compliance for these dosage forms in the European Union follows Regulation (EU) 2019/6 for veterinary medicinal products when marketed, while extemporaneous preparation under national veterinary pharmacy provisions may apply for non-food species; for game birds intended for human consumption, residue status under Table 1 of the Annex to Commission Regulation (EU) No 37/2010 must be verified before any off-label use. Release testing references USP 905 for uniformity of dosage units and USP 701 for disintegration; microbial quality is assessed under the relevant pharmacopoeial microbial examination method. Wet granulation is preferred over direct compression because unmilled nicarbazin fines coat punch faces and cause weight variability above ±3% RSD on single-punch machines. The process uses a high-shear granulator for 3–5 min, a tray or fluid-bed dryer with product temperature not exceeding 50°C, dry sieving through 500–800 µm screens, and a rotary tablet press with 8–10 mm round punches; pre-compression force is set at 2–4 kN to expel air from the granulate. Capsule products are manufactured by filling the same granulate into hard gelatin or hydroxypropyl methylcellulose capsules using an automatic capsule filler with tamping pins adjusted to compact the granulate to 0.6–0.8 g/cm³ tapped density. Terminal finished forms are compressed tablets, hard capsules, and powder-filled capsules for non-food avian coccidiosis management; the absence of a food-producing residue statement should be confirmed before shipment into jurisdictions that restrict extralabel use in pigeons or exotic birds.

True molecular solutions of nicarbazin for drinking-water medication are not achievable with conventional water-based vehicles because the compound falls into the practically insoluble compendial class; liquid formulations are therefore micro- or nanosuspensions stabilized by wetting agents and viscosity modifiers. A 50 mg/mL oral suspension can be built from 5% w/v nicarbazin, 0.1–0.5% w/v polysorbate 80, 0.2–0.5% w/v xanthan gum or sodium carboxymethylcellulose, and a preserved aqueous vehicle; nanosuspensions intended for oral gavage in avian medicine are typically processed at 10–50 mg/mL because higher solids content reduces homogenizer throughput and increases sedimentation. The production route uses a rotor–stator mixer to wet the API, followed by high-pressure homogenization at 800–1000 bar for 5–15 passes until the particle-size distribution D90 falls below 1 µm; a zeta potential of ≤−30 mV is maintained to suppress Ostwald ripening and sedimentation. Regulatory status depends on the intended species: for food-producing birds, water-based nicarbazin products must meet the MRL entries and withdrawal periods under Table 1 of the Annex to Commission Regulation (EU) No 37/2010; for non-food zoo birds or pigeons, national veterinary pharmacy rules under Regulation (EU) 2019/6 apply. Sedimentation in drinker lines remains a practical constraint because the suspension can settle at low-flow dead legs; peristaltic recirculation or low-shear agitation is required in primary mixing tanks. Terminal products are oral suspensions, oral pastes, and gavage dispersions for non-food avian species; published data for this specific configuration in large-scale water lines is limited. The same insolubility barrier precludes ordinary injectable product development: no authorised commercial parenteral formulation exists, and sterile suspension work would require a separate preformulation programme with syringeability, sterility, and tissue tolerance testing before any clinical use could be contemplated.

When a feed mill cannot introduce nicarbazin, farm-level top-dress powders shift mixing duty to the flock manager

A 1% w/w nicarbazin top-dress powder is designed for small batches in which the entire daily feed quantity is not available for feed-mill medication; to deliver 100–125 mg/kg active, 250–312.5 g of the 1% w/w powder is added to 25 kg of feed. The regulatory basis is narrower than feed-mill premix use because in many jurisdictions farm-level medicated feed mixing is not permitted for food-producing broilers; application for non-food poultry or under veterinary prescription must follow national regulations and the prescribing veterinarian's written directions. Feed-additive status under Regulation (EC) No 1831/2003 applies to the source nicarbazin, but the act of farm-level blending may be controlled separately as extemporaneous medicated feed preparation. Mixing on farm uses a clean 50 kg drum mixer or a paddle mixer dedicated to medicated feed, with geometric dilution of the top-dress powder into 2–5 kg of carrier feed before introduction to the remaining feed; mixing time should be verified with a salt tracer or riboflavin tracer to achieve a CV <10%. Segregation is the dominant failure mode because the top-dress powder and whole grains differ in particle size; the carrier should be ground corn or soybean meal passing through a 500–800 µm screen. Terminal finished products are single-dose sachets, farm-mix packets, and calibrated scoop packs for small breeders and non-food flocks. Unused medicated feed must not be diverted to other species, and mixing equipment must be cleaned by flushing with unmedicated carrier feed for 5–10 min to prevent carryover into later withdrawal-period rations.